Dr. Deol on the Curative Potential of CAR T-Cell Therapy in ALL

Abhinav Deol, MD, associate clinical professor, Barbara Ann Karmanos Cancer Institute, discusses the role of CAR T-cell therapy in pediatric patients with acute lymphoblastic leukemia (ALL).

Data have shown encouraging rates of complete remission (CR) among pediatric patients with ALL who are treated with CAR T-cell therapy, Deol says.

As such, CAR T-cell therapy may offer a potentially curative treatment option in this setting.

However, older patient​s with ALL who achieve a CR with CAR T-cell therapy require subsequent allogenic stem cell transplants to prevent relapse, Deol concludes.